Last updated: 11/03/2018 11:33:47

Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Saudi Arabia

GSK study ID
111337
Clinicaltrials.gov ID
NCT01204385
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Saudi Arabia
Trial description: The purpose of the study is to identify the bacterial aetiology of acute otitis media episodes in young children aged ≥ 3 months to < 5 years in Saudi Arabia.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Occurrence of H. influenzae, S. pneumoniae and other bacterial pathogens isolated from middle ear fluid samples

Timeframe: Average time frame: 12 months

Secondary outcomes:

Occurence of H. influenzae and S. pneumoniae serotypes

Timeframe: Average time frame: 12 months

Antimicrobial susceptibility of H. influenzae, S. pneumoniae and Moraxella catarrhalis isolated from middle ear fluid samples as assessed by standard microbiological techniques

Timeframe: Average time frame: 12 months

Occurrence of treatment failure of acute otitis media and of recurrent acute otitis media (≥ 3 episodes in the last 6 months or ≥ 4 episodes in 12 months)

Timeframe: Average time frame: 12 months

Occurrence of spontaneous otorrhea

Timeframe: Average time frame: 12 months

Occurrence of H. influenzae in acute otitis media cases with treatment failure and in new acute otitis media cases without treatment therapy

Timeframe: Average time frame: 12 months

Occurrence of H. influenzae in acute otitis media cases vaccinated with a pneumococcal vaccine

Timeframe: Average time frame: 12 months

Interventions:
  • Procedure/surgery: Sample collection
    • Enrollment:
    66
    Primary completion date:
    2011-16-05
    Observational study model:
    Case-Only
    Time perspective:
    Prospective
    Clinical publications:
    Not applicable
    Medical condition
    Infections, Streptococcal
    Product
    GSK2647154A
    Collaborators
    Not applicable
    Study date(s)
    June 2009 to May 2011
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    3 months - 5 years
    Accepts healthy volunteers
    No
    • A child will be eligible for inclusion if he/she meets the following criteria:
    • Age: ≥ 3 months and < 5 years at the time of enrolment. The subject becomes ineligible on the fifth birthday.
    • The following criteria should be checked at the time of study entry. If any apply, the child must not be included in the study.
    • Hospitalised during the diagnosis of AOM or during treatment,
    Inclusion and exclusion criteria
    Inclusion criteria:
    • A child will be eligible for inclusion if he/she meets the following criteria:
    • Age: ≥ 3 months and < 5 years at the time of enrolment. The subject becomes ineligible on the fifth birthday.
    • Signs, symptoms, and conditions: i. One of the functional or general signs of otalgia (or its equivalent: irritability), conjunctivitis, fever AND EITHER ii. Paradise's criteria (bulging, diffused or localised inflamed tympanic membranes) OR iii. Spontaneous otorrhoea of less than 24 hours
    • Onset of signs and symptoms of AOM within 72 hours prior to diagnosis of AOM by a physician. To be included as treatment failure, subjects must have then received antibiotic treatment from the physician, but remain symptomatic 48-72h after initiation of treatment
    • Written informed consent obtained from parent or guardian prior to study start.
    Exclusion criteria:
    • The following criteria should be checked at the time of study entry. If any apply, the child must not be included in the study.
    • Hospitalised during the diagnosis of AOM or during treatment,
    • Otitis externa, or otitis media with effusion
    • Presence of a transtympanic aerator
    • Systemic antibiotic treatment received for a disease other than AOM in the 72 hours prior to enrolment,
    • Receiving antimicrobial prophylaxis for recurrent AOM,
    • Provision of antibiotic by paediatrician/ENT specialist at the enrolment visit, prior to the sampling
    • Patients on antibiotics for AOM who are clinically improving.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Riyadh, Saudi Arabia
    Status
    Study Complete
    Contact us

    Study documents

    No study documents available.

    Results overview

    No study documents available

    Recruitment status
    Study complete
    Actual primary completion date
    2011-16-05
    Actual study completion date
    2011-16-05

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website